Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 125

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 125
---
 obligations primarily consist of lease payments and purchase order obligations. Premises
leasing obligations represent our commitment for future lease payments under the lease agreement for our facilities in Modi’in,
Israel and Waltham, Massachusetts (which is not being utilized following shutdown of our U. S. commercialization activities in the fourth
quarter of 2024). The total future payments for our premises leasing obligations on December 31, 2024 were approximately $1.9 million
which is due through June 2030. Purchase order obligations amounted to $2.0 million as of December 31, 2024. For additional details regarding
our contractual obligations, see Note 10 to our audited financial statements included in this Annual Report on Form 20-f.

In addition, under our in-licensing agreements, we are obligated
to make certain payments to our licensors upon the achievement of agreed-upon milestones and receipt of royalties. We are unable at this
time to estimate the actual amount or timing of the costs we will incur in the future under these agreements. Some of the in-licensing
agreements are accompanied by consulting, support and cooperation agreements, pursuant to which we are required to pay the licensors a
fixed monthly amount, over a period stipulated in the applicable agreement, for their assistance in the continued research and development
under the applicable license. All of our in-licensing agreements are terminable at-will by us upon prior written notice of 30 to 90 days.
We are unable at this time to estimate the actual amount or timing of the costs we will incur in the future under these agreements. See
“ Item 4. Information on the Company - Business Overview - In-Licensing Agreements.”

C. Research and Development, Patents and Licenses

For our research and development policies, see “ Item 4. B.
 - Information on the Company - Business Overview - Our Strategy.” For information regarding patents, see “ Item
4. B. - Information on the Company - Business Overview - Intellectual Property.” For information regarding licenses,
see “ Item 4. B. - Information on the Company - Business Overview - Collaboration and Out-Licensing Arrangements”
and “ Item 4. B. - Information on the Company - Business Overview - In-Licensing Agreements.”

D. Trend Information

We are a biopharmaceutical company pursuing life-changing therapies
in oncology and rare diseases. To date, we have generated only limited direct product revenues from independent commercialization activities,
following the